



PHARMACY POLICY STATEMENT

North Carolina Marketplace and Caroro2 (TETQ) 247.7



If all the above requirements are met, the medication will be approved for 1 month.

For reauthorization :

1. Zolgensma will not be reauthorized for continuous use.

CareSource considers Zolgensma (onasemnogene abeparvovec- xioi) not



13. Novartis Gene Therapies, Inc. Pre-Symptomatic Study of Intravenous Onasemnogene Apeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients with Multiple Copies of SMN2 (SPR1NT). Jan 2022. Available from: <https://clinicaltrials.gov/ct2/show/NCT03505099>
14. spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022. <https://doi.org/10.1038/s41591-022-01866-4>.
15. Strauss KA, et al. Onasemnogene ab spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022. <https://doi.org/10.1038/s41591-022-01867-3>.

Effective date: 01/01/2023

Revised date: 05/24/2022